Nonmelanoma skin cancers (NMSC) are among the most common malignancies in the world. Typically, these neoplasms grow slowly and are comparatively indolent in their clinical behavior. The most frequent molecular alterations implicated in the pathogenesis of these neoplasms involve genes known to be regulators of cell death including p53, Ha-ras and bcl-2. In order to evaluate the signi®cance cell death deregulation during skin carcinogenesis, we generated a transgenic mouse model (HK1.bcl-2) using the human keratin 1 promoter to target the expression of a human bcl-2 minigene to the epidermis. Transgenic HK1.bcl-2 protein was expressed at high levels speci®cally in the epidermis extending from the stratum basale through the stratum granulosum. The epidermis of HK1.bcl-2 mice exhibited multifocal hyperplasia without associated hyperkeratosis and aberrant expression of keratin 6. The rate of proliferation was similar in HK1.bcl-2 and control epidermis although suprabasal BrdUrd incorporating cells were present only in HK1.bcl-2 skin. Keratinocytes from the HK1.bcl-2 mice were signi®cantly more resistant to cell death induction by U.V.-B, DMBA, and TPA, compared to control keratinocytes. Furthermore, papillomas developed at a signi®cantly greater frequency and shorter latency in the HK1.bcl-2 mice compared to control littermates following initiation with DMBA and promotion with TPA. Together these results support a role for bcl-2 in the pathogenesis of NMSC.
Introduction
Nonmelanoma skin cancer (NMSC) is the most common malignancy in humans, representing nearly 40% of all cancers diagnosed in the United States (Wingo et al., 1995; Parker, et al. 1996) . The two most common types of NMSC are basal cell carcinoma (BCC), and squamous cell carcinoma (SCC). It is now widely recognized that cancer is a multistep process that in large part is genetically determined (Bishop, 1991) . It is now also appreciated that the rate of tumor growth is not simply a function of mitotic activity but is also greatly in¯uenced by the rate of cell death or apoptosis. Among the most frequent molecular events implicated in the pathogenesis of NMSC are inactivating mutations in the p53 tumor suppressor gene and activating mutations of the Ha-ras oncogene (Burns et al., 1991; Kanjilal et al., 1993; Rady et al., 1992 , Quintanilla et al., 1986 Pierceall et al., 1991) . The p53 and Ha-ras gene products, in addition to their role in regulating cell cycle progression, are known to be regulators of apoptosis (Yonish-Rouach et al., 1991 , Shaw et al., 1992 Lowe et al., 1993; Clarke et al., 1993) .
One of the best characterized cell death regulators is the bcl-2 oncogene (Yang and Korsmeyer, 1996) . Its oncogenic potential has been shown to result from the inhibition of apoptotic cell death and not from enhanced cell proliferation (McDonnell and Korsmeyer, 1991) . Dierent members of the bcl-2 gene family are expressed in the epidermis. Bcl-2 appears exclusively localized in the basal layer of the epidermis and is present in some epidermal appendages (Stenn et al., 1994; RodrõÂ guez-Villanueva et al., 1995; Hockenbery et al., 1991) . The distribution of bcl-2 protein in the adult skin indicates that the expression of bcl-2 does not precisely correlate with a stem cell phenotype but more closely correlates with the dierentiation status of the cell. Conversely, bcl-x protein is more abundant in the upper layers of the epidermis (Krajewski et al., 1994a) . Bax is weakly expressed in all strata of the epidermis (Krajewski et al., 1994b) . More recently bak expression has been reported to be quite intense in all epidermal nucleated compartments reaching its maximum level within the granular cell layer (Krajewski et al., 1996) .
The ability to generate genetically engineered strains of mice by targeting tissue-speci®c activation of oncogenes to the epidermis provides a powerful technique for the study of skin carcinogenesis (Rothnagel et al., 1990; Zinkel and Fuchs, 1994) . Multiple examples of this strategy applied to the study of skin carcinogenesis have been recently summarized (Zinkel and Fuchs, 1994; Greenhalgh et al., 1995; Brown and Balmain, 1995; Arbeit, 1996) . To further evaluate the signi®cance of these observations and to study the eects of cell death deregulation during skin carcinogenesis, we generated a transgenic mouse model (HK1.bcl-2) using the human keratin 1 promoter to target the expression of a human bcl-2 minigene to the epidermis.
Results
A total of eighteen pups were born from embryos microinjected with the HK1.bcl-2 construct. Of the 18 founder mice, six (three males and three females) were identi®ed as bearing the transgene in somatic cells. Five of the six HK1.bcl-2 transgenic animals possessed germline integration and were able to transmit the transgene to subsequent generations. The transgenic animals were born with the expected Mendelian frequency and were phenotypically indistinguishable from control littermates.
Expression of the human transgenic bcl-2 protein in the epidermis was con®rmed by immunostaining of newborn mouse skin sections using a hamster monoclonal antibody (6C8) speci®c for human bcl-2. Protein expression was found in all the layers of the epidermis except the stratum corneum (Figure 1) . Absence of bcl-2 staining in the skin of control mice veri®ed the species speci®city of the anti-bcl-2 antibody. Levels of transgenic bcl-2 protein were compared to endogenous murine bcl-2 protein in the epidermis by Western blot analysis (Figure 2 ). Protein levels were normalized to actin control levels. Levels of the transgenic bcl-2 protein were found to be 2 ± 6 times greater than the corresponding endogenous bcl-2 protein. No dierence in the levels of endogenous bcl-2 protein was observed between control and transgenic mice. Western blotting of lysates from a variety of organs including lung, brain, heart, thymus, skeletal muscle, kidney, liver, spleen, stomach and bladder revealed that transgenic bcl-2 protein was expressed exclusively in the epidermis (not shown).
Tissue sections of newborn mouse skin were stained by hematoxylin and eosin and examined by light microscopy. The epidermis, in general, appeared histologically normal both in thickness and extent of keratinization. However, focal areas of epidermal hyperplasia, without associated hyperkeratosis, were frequently observed in the skin of HK1.bcl-2 mice (Figure 3 ).
The presence of hyperplastic foci prompted the evaluation of proliferative activity in the epidermis of the transgenic mice. In vivo labeling of dividing cells was accomplished by injecting newborn transgenic and control mice intraperitoneally with a sterile solution of Figure 1 Expression of transgenic human bcl-2 protein in the epidermis. Immunohistochemical staining of a thin section of skin from a newborn HK1.bcl-2 transgenic mouse using the hamster anti-human bcl-2 monoclonal antibody 6C8. Transgenic protein appears localized in the cytoplasm of most of the cells of all layers of the epidermis but not in the stratum corneum. 8006magni®cation
Figure 2 Western blot analysis of bcl-2 protein expression in skin of newborn mice. Skin protein extracts from control and HK1.bcl-2 transgenic newborn mice were analysed by Western blot using hamster monoclonal antibodies speci®c against the human (6C8) and murine (3F11) bcl-2 proteins. Samples S34/4, S37/1, and S39/4, derived from HK1.bcl-2 transgenic mice, show a 25 Kd band after blotting with both antibodies. Samples S34/5, S38/3 and S38/2, from control animals, only presented the band corresponding to the endogenous bcl-2. Protein extracts from a human B cell lymphoma line with a t(8;14) translocation, expressing high levels of bcl-2 and from mouse thymus were used as positive controls for the 6C8 and 3F11 monoclonal antibodies, respectively Figure 3 Histologic appearance of the skin of the HK1.bcl-2 transgenic mice. Top: Hematoxylin and eosin staining of a skin section of a a control newborn mouse. Bottom: A skin section from a HK1. (Figure 4) . A panel of antibodies speci®c for proteins expressed at de®ned stages of epidermal dierentiation were used to assess whether the expression of the HK1.bcl-2 transgene had any impact on keratinocyte maturation. The patterns of expression of murine keratins 1, 10 and 14, as well as loricrin and ®laggrin, imaged by twocolor immuno¯uorescence microscopy, were similar in the control and transgenic newborn animals (not shown). Murine keratin 13 was also undetectable in both HK1.bcl-2 transgenic and control mice. Murine keratin 6 is a marker of epidermal hyperproliferative activity, and is normally expressed in the hair follicle bulge. Keratin 6 expression is upregulated in the interfolicular epidermis following dierent types of injuries such as mechanical, chemical or thermal irritation, or in speci®c pathological processes including psoriasis. Interestingly, in the HK1.bcl-2 transgenic mice, keratin 6 was aberrantly expressed throughout the epidermis and was not associated with any histologic alteration in the skin ( Figure 5 ). The foci of epidermal hyperplasia also intensely expressed keratin 6 ( Figure 5 ). Control littermates exhibited appropriate distribution of keratin 6 within the skin, i.e., only in the outer root sheath of the hair follicles.
\Figure 4 Epidermal proliferative activity in HK1.bcl-2 newborn mouse. Newborn mice were intraperitoneally injected within the ®rst day of life with a sterile solution of BrdUrd. Skin samples collected 1 h after injection were histological processed, stained with a FITC-tagged anti-BrdUrd monoclonal antibody, and analysed by¯uorescence microscopy. A Texas red labelled antimurine K14 monoclonal antibody counterstaining allowed the de®nition of the epidermis. Top: dividing BrdUrd positive keratinocytes appear both in the basal and suprabasalar layers within the epidermal hyperplastic focus of a HK1.bcl-2 transgenic mouse. Bottom: skin section from a control newborn mouse shows the typical pattern of dividing cells exclusively localized in the basal stratum of the epidermis. 8006 magni®cation Figure 5 Aberrant keratin 6 expression in the epidermis of HK1.bcl-2 transgenic mice. Skin sections from newborn mice were stained with a FITC-labeled monoclonal antibody speci®c against murine K6, counterstained with a Texas red tagged anti-murine K14 monoclonal antibody, and analysed by¯uorescence microscopy. Top: K6 expression in control mouse skin is limited to the hair follicles. Center: Aberrant epidermal K6 expression in most of the layers of a section of the interfollicular epidermis of normal thickness derived from a HK1.bcl-2 transgenic mouse. Bottom: Aberrant K6 protein expression also occurs within foci of epidermal hyperplasia characteristic of the HK1.bcl-2 transgenic mice. 5006 magni®cation The number of spontaneous apoptotic cells within the epidermis was assessed in both control and transgenic newborn mouse samples using the TUNEL method. No dierences between the transgenic and control mice were detected. Approximately one cell in 100 nucleated epidermal cells was TUNEL positive. Induction of apoptosis in the epidermis was also examined following exposure to U.V.-B light. Both control and HK1.bcl-2 transgenic, received a single dose of about 2 KJ/m 2 of U.V.-B, and were sacri®ced at 6 and 24 h after treatment. The number of apoptotic cells within the epidermis at 6 h was similar to untreated samples with an apoptotic index of 0.8% in controls and 0.7% in HK1.bcl-2 transgenics (P = 0.45). However, at 24 h the apoptotic index of the control mice increased to 13.8+1.8%, while the apoptotic index for the transgenic mice increased to only 6.4+2.4% (P 4 0.001) ( Figure 6 ). Therefore, expression of bcl-2 within the epidermis provided signi®cant protection from cell death induction by ultraviolet irradiation.
Chemical carcinogenesis was assessed in 46 transgenic and 30 control newborn mice using topical application of 20 mg of DMBA at post-natal day 1 followed by topical TPA (2.5 mg) twice weekly for 3 weeks followed by 5 mg of TPA for 30 weeks ( Figure  7 ). Mice receiving treatment with solvent alone (negative control) never developed papillomas. Tumor frequency and tumor size was assessed at weekly intervals during the period of observation. A maximum of 61% of HK1.bcl-2 transgenic mice developed papillomas compared to 36% of the control littermate mice (P40.03). The latency period to tumor development in the transgenic group was 14.9+6.3 weeks and was signi®cantly shorter than the 20.7+7.6 week latency period in the control littermate mice (P4 0.002). The average number of papillomas per transgenic mouse, 2.04+1.31, was not signi®cantly dierent than that of control mice, 1.8+1.14 (P=0.3). The papillomas arising in the transgenic mice were, on average, larger than those arising in the control littermates although this dierence did not achieve Primary cultures of keratinocytes derived from both control and HK1.bcl-2 mice were used to directly assess the eect of U.V.-B, DMBA, and TPA on keratinocyte viability. A signi®cant dierence in viability was observed between keratinocytes derived from transgenic mice compared to control animals after treatment with U.V.-B light (Figure 8 ). The viability of the untreated cells of both groups remained within the range of 80% during the time period of observation. Only 55.17+4.6% of the control cells were viable, as assessed by trypan blue exclusion, 12 h after receiving 200 J/m 2 of U.V.-B, compared to a corresponding viability of 78.85+1.1% for HK1.bcl-2 keratinocytes (P40.002). Control keratinocyte viability was reduced to 11.93+4.7% 30 h after receiving a 1000 J/m 2 of U.V.-B compared to a viability of 30.93+11.0% for HK1.bcl-2 keratinocytes (P40.01).
Treatment with DMBA also resulted in reduction in viability in both control and HK1.bcl-2 derived primary keratinocytes (Figure 9 ). A decrease in control keratinocyte viability was apparent at 24 h and reached maximal levels at 72 h after treatment with 0.5 ± 0.05 mg/ml of DMBA. Keratinocytes derived from HK1.bcl-2 transgenic mice were protected from DMBA-associated cytotoxicity and exhibited significantly greater viability at 72 h compared to control keratinocytes (P40.01). Control keratinocytes were also very sensitive to the cytotoxic eects of TPA, exhibiting a viability of only 15.82+4.8% after 72 h of treatment with 10 mM TPA (Figure 10 ). HK1.bcl-2 transgenic cells exhibited signi®cantly enhanced viabi- Figure 9 Cytotoxic eect of DMBA treatment on primary keratinocytes derived from control or HK1.bcl-2 mice. Primary keratinocytes derived from control (left panel) or HK1.bcl-2 transgenic (right panel) mice were treated with 0.5 mg/ml (triangles), 0.25 mg/ml (squares), 0.05 mg/ml (asterisk), or 0 mg/ ml of DMBA (circles), and cell viability assessed at 24 h intervals by trypan blue exclusion over a 72 h period Figure 10 Cytotoxic eect of TPA treatment on primary keratinocytes derived from control or HK1.bcl-2 mice. Primary keratinocytes derived from control (left panel) or HK1.bcl-2 transgenic (right panel) mice were exposed to 10 mM (triangles), 25 mM (squares), or 0 mM TPA (circles), and cell viability assessed by trypan blue exclusion over a 72 h period. Control keratinocytes were signi®cantly more sensitive compared to HK1.bcl-2 transgenic cells 1 2 3 4 5 6 7
Figure 11 Internucleosomal DNA degradation (`ladders') in primary keratinocytes induced by treatment with U.V. DNA agarose gel electrophotresis and cell morphology were used in order to assess the ability of U.V.-B, DMBA, and TPA to induce apoptosis in primary keratinocytes. DNA isolated from control animal derived keratinocytes after treatment with each of these agents was electrophoresed and demonstrated the presence of internucleosomal DNA cleavage (`ladders') characteristic of apoptosis (Figure 11 ). Control keratinocytes treated with these agents were also stained with calcein AM/ethidium homodimer-1 and visualized with¯uorescence microscopy. These cells exhibited morphologic features consistent with apoptosis, including nuclear pyknosis and formation of apoptotic bodies (Figure 12 ).
Discussion
An imbalance in the rates of cell proliferation and cell death is considered to be an important event during the pathogenesis of many human tumors. This imbalance may be re¯ected in an enhanced rate of proliferation and/or a decreased susceptibility to undergo apoptotic cell death. In fact, the most common malignancies, including low grade lymphomas, skin cancer, and prostate cancer are characterized, initially, by a period where the rate of cell division does not exceed that of the normal tissue of origin. It is relevant, in this regard, that the molecular lesions which occur frequently in NMSC involve genes which are known to regulators of proliferation as well as cell death. The immunohistochemical observations concerning bcl-2 gene expression in NMSC suggests the possibility that bcl-2 deregulation may be important in the pathogenesis of at least some of these malignancies (RodrõÂ guez-Villanueva et al., 1995) . In order to prospectively examine the contribution of deregulated bcl-2 expression and the inhibition of apoptosis to multistep carcinogenesis in the skin, we engineered a minigene construct to target the expression of human bcl-2 to the epidermis. Western blot analysis indicated that levels of bcl-2 protein generated from expression of the HK1.bcl-2 transgene exceeded that of the endogenous bcl-2 gene by 2 ± 6-fold. Immunohistochemical analysis of frozen-sectioned skin from HK1.bcl-2 transgenic mice and control littermates showed that the human bcl-2 transgenic protein was distributed from the basal keratinocytes through the stratum granulosum. On the basis of the Western blot analysis and immunohistochemistry it may be stated that the HK1.bcl-2 transgene results in the deregulated expression of bcl-2 in terms of absolute amounts of bcl-2 protein and the distribution of bcl-2 protein within the epidermis. An analysis of other organ sites con®rmed that expression of the HK1.bcl-2 transgene was limited to the epidermis.
Importantly, the histomorphology of the epidermis of the HK1.bcl-2 mice was altered, exhibiting multifocal areas of hyperplasia. These hyperplastic foci, in contrast to those observed in the HK1.v-Ha-ras animals, were not associated with hyperkeratosis nor did they exhibit dysplastic features (Greenhalgh et al., 1993) . It would be reasonable to anticipate that the uniform and high levels of bcl-2 protein produced in the epidermis of the HK1.bcl-2 mice would result in a generalized and not multifocal, hyperplasia. This observation may indicate that compensatory, homeostatic mechanisms are operative which, in general, restore the normal rate of keratinocyte turnover. It might, therefore, be anticipated that the proliferative rate within the epidermis of the HK1.bcl-2 transgenic would be lower than that of control littermate mice. However, steady-state levels of proliferation, as assessed by incorporation of BrdUrd was comparable in HK1.bcl-2 and control mice. It is conceivable that the mechanism of cell death induction in the normal epidermis proceeds via a bcl-2 independent mechanism. The absence of demonstrable alterations in the histologic appearance of the skin in bcl-2`knock-out' mice would be consistent with this interpretation (Veis et al., 1993) . Alternatively, it is possible that the foci of epidermal hyperplasia observed in the HK1.bcl-2 mice re¯ect dierences within the complex microenvironment of the skin. The ®ndings indicate that deregulated expression of bcl-2 may be necessary, but not sucient, to induce epidermal hyperplasia and suggest that physiologic feedback mechanisms may be operative within the skin which limit the neoplastic potential resulting from oncogene activation. Interestingly, foci of epidermal hyperplasia, similar to those observed in the HK1.bcl-2 transgenic mice, have recently been characterized as the earliest lesion associated with the application of DMBA plus TPA. Meticulous follow-up of these epidermal`micropapullae' revealed that they developed into the characteristic papillary tumors induced by this chemical carcinogenesis protocol. Foci of hyperplasia within the epidermis of the HK1.bcl-2 transgenic mice were not associated with a demonstrable increase in keratinocyte proliferation as demonstrated by in vivo labeling of dividing cells with BrdUrd. However, within these areas of epidermal hyperplasia proliferative cells were not con®ned to the stratum basale, indicating that the loss of proliferative potential associated with keratinocyte dierentiation could be delayed in the context of deregulated bcl-2 expression.
The epidermis of the bcl-2 transgenic mice also displayed aberrant expression of cytokeratin 6. Keratin 6, considered a marker of keratinocyte proliferation, is speci®cally expressed in the outer root sheath of hair follicles in normal skin (Heid et al., 1988; Moll et al., 1982; Quilan et al., 1985; Stark et al., 1987) . Keratin 6 is also a marker of epidermal irritation and injury and is highly expressed by keratinocytes involved in wound healing, eczema, or psoriasis (Mansbridge and Knapp, 1987; Moll et al., 1982; Schweizer and Winter, 1982) . Immuno¯uorescence staining of sections of HK1.bcl-2 mouse skin revealed intense K6 immunoreactivity within the interfolicular epidermis. Typically, keratin 6 was expressed in all strata of the epidermis, excluding the stratum corneum and was uniformly expressed in foci of epidermal hyperplasia. This observation, as far as we are aware, represents the ®rst demonstration in which the deregulated expression of bcl-2 is associated with the aberrant expression of a dierentiation stage speci®c biochemical marker. This observation suggests that bcl-2 may regulate other processes within the cell which are not strictly associated with the inhibition of apoptosis per se. It has previously been suggested that bcl-2 may not be limited to the regulation of apoptosis but may also, directly or indirectly, act as a central control of dierentiation (Marthinuss et al., 1995) . While expression of keratin 6 is frequently associated with increased proliferative activity, these two events can clearly be dissociated within keratinocytes (Sellheyer et al., 1993) .
The importance of bcl-2 expression in controlling the susceptibility of keratinocytes to undergo cell death induction was demonstrated both in vivo and in vitro in response to U.V.-B irradiation. Apoptotic, or`sunburn', cells within the epidermis are recognized by the acquisition of morphologic alterations clearly visible on hematoxylin and eosin stained tissue sections. The spontaneous rate of apoptosis occurring within the epidermis of HK1.bcl-2 transgenic mice was indistinguishable from that observed in control littermate mice. However, 24 h after exposure to a single dose of U.V.-B light, the frequency of HK1.bcl-2 sunburn cells was less than half that induced in control littermate mice. Similarly, U.V.-B induced cell death in cultured primary keratinocytes from HK1.bcl-2 mice was signi®cantly less than that observed in keratinocytes from control littermate mice.
Similar to the HK1.bcl-2 mice, a decrease in the number of apoptotic keratinocytes after in vivo U.V.-B irradiation has been also been reported in p53 nullizygous mice (Ziegler et al., 1994) as well as keratin 14-bcl-x L transgenic mice (Pena et al., 1997) compared to control littermates. This suggests that constitutively expressed bcl-2 could suppress p53 mediated apoptotic cell death as has been demonstrated in several experimental systems (Chiou et al., 1994; MarõÂ n et al., 1994; Wang et al., 1993) . It remains to be determined with respect to the development of cutaneous malignancies the extent to which p53 and bcl-2 overlap in the regulation of apoptosis. Ongoing studies are in progress to evaluate the relationship and extent of synergy between constitutive bcl-2 expression and p53 inactivation. It may be anticipated that decreasing the susceptibility of keratinocytes to undergo apoptosis in response to DNA damage would accelerate carcinogenesis.
In fact, the suppression of cell death may be of general signi®cance in the development of cutaneous malignancies in that DMBA and TPA are potent inducers of apoptosis in keratinocytes. Treatment with these agents resulted in the generation the morphological features of apoptosis and formation of typical DNA ladders characteristic of oligonucleosomal DNA degradation. The inactivation of p53, via somatic mutation, or the upregulation of a cell death suppressing oncoprotein such as bcl-2 represents a selective advantage in this context and enables cells with damaged, or mutated, DNA to remain viable. Consistent with this hypothesis was the signi®cant reduction in apoptosis observed in primary keratinocytes isolated from HK1.bcl-2 transgenic mice following treatment with DMBA or TPA compared to keratinocytes isolated from control littermate mice.
The HK1.bcl-2 transgenic mouse is characterized by a multifocal and, presumably, polyclonal epidermal hyperplasia. Spontaneous conversion to a malignant phenotype was not observed in the HK1.bcl-2 transgenic mouse so that it is clear that the deregulated expression of bcl-2 in the HK1.bcl-2 transgenic mouse, as in other bcl-2 transgenic models (McDonnell et al., 1989; McDonnell and Korsmeyer, 1991) , is not sucient to generate a malignant phenotype. The use of DMBA followed by serial applications of TPA resulted in the induction of papillomas at a signi®cantly higher frequency in HK1.bcl-2 compared to control littermate mice (P40.03). The latency to tumor formation was also signi®cantly reduced in the HK1.bcl-2 transgenic mice compared to the control littermates (P40.002). Together, these results indicate that the deregulated expression of bcl-2 is able to accelerate the rate of cutaneous tumor formation in a classic chemical carcinogenesis protocol. These studies are still in progress in order to assess the rate of malignant conversion following cessation of promoter treatment. These ®ndings further support the contention that the high levels of bcl-2 protein observed in certain types of NMSC is of biologic signi®cance.
In summary, we have developed a new experimental animal model to study cell death deregulation in the skin by targeting expression of bcl-2 speci®cally to the epidermis. Studies done in our laboratory, as well as others, have demonstrated that alterations in the expression of bcl-2 gene family members occurs frequently in human NMSC. Altered expression of the bcl-2 family of cell death regulatory proteins may have profound impact on normal development as well as predispose to neoplastic growth. Our results demonstrate that constitutive bcl-2 expression can alter the expression of K6 in epidermal keratinocytes. Furthermore, keratinocytes expressing high levels of bcl-2 protein are resistant to cell death induction by several mutagenic agents, including U.V.-B irradiation, which are implicated in the pathogenesis of NMSC. Our ®ndings suggest that enforced bcl-2 expression may result in the accelerated development of skin neoplasms. These studies have provided the foundation for ongoing and future studies to further elucidate the signi®cance of cell death deregulation in the the skin.
Materials and methods

Construction of the HK1.bcl-2 Transgene
The HK1 epidermal targeting vector was designed by Rothnagel et al., (1990) . It is based on a 12 KbEcoRI fragment of the human keratin 1 (HK1) gene (Johnson et al., 1985) . The fragment has been modi®ed to enable its expression in both basal cells as well as in the suprabasalar layers of the epidermis except the stratum corneum (Rosenthal et al., 1991) . The targeting vector consists of the 5'¯anking region up to, but not including, the ATG codon, the ®rst intron including the splice site of the intron/exon boundary, and all of the HK1 3' noncoding and¯anking sequences after the TAA codon. The ®rst intron was retained to ensure message stability, as well as the 3' noncoding region, to preserve signi®cant control elements involved in targeting and ecient expression (Rosenthal et al., 1991) . A polylinker segment containing several unique restriction enzyme sites was engineered immediately 3' to the ®rst intron to allow the insertion of the selected DNA coding sequences. The unique EcoRI sites at the vector ends were retained, and the vector was cloned into a pGEM3 plasmid for bacterial replication and ampli®cation (Rothnagel et al., 1990) . The HK1.bcl-2 construct was generated by introducing a 720 bp fragment from the human bcl-2 cDNA58 clone (Seto et al., 1988) containing the open reading frame at the KpnI restriction site of the polylinker region of the HK1 expression vector. Correct transcriptional orientation of the bcl-2 insert was determined by restriction enzyme digestion patterns and DNA sequencing was performed to rule out base misincorporation. The ®nal size of the HK1.bcl-2 construct was 7.4 Kb. Using standard microinjection techniques, the 7.4 Kb HK1.bcl-2 construct was introduced into the pronuclei of single cell C57BL/6x SJL F2 hybrid mouse embryos. These embryos were re-implanted into the uterine tubes of pseudo-pregnant foster female mice.
Identi®cation of transgenic HK1.bcl-2 mice
Mouse pups were screened for the presence of the transgene using a PCR based strategy with oligonucleotide primers speci®c for the intron 1 of the transgenic construct. DNA isolated from tail biopsies served as template for the PCR analysis. The pGEM.PHK1.bcl-2 vector constituted the positive control, and tail DNA from non-transgenic mice was used as a negative control. A blank reaction tube (without template DNA) was also included to rule out contamination of the common reagents. Vector speci®c oligonucleotide primers were as follows: HK-J11: 5'-TGGTCCACTTGGGATTGGTG-3'; HK-J18: 5'-GGA GTCTCATAGCCATGG-3'.
The PCR reaction consisted of 30 cycles under the following conditions: Denaturing: 958C, 30; Annealing: 608C, 1 min; Extension: 728C, 1 min. An initial denaturing cycle (958C, 5 min) and a ®nal extension cycle (728C, 15 min) were used to optimize the eciency of the reaction. The resulting 845 bp DNA fragment was identi®ed by ethidium bromide staining following elecrophoresis in a 1% agarose gel using the φX174 HindIII molecular weight marker (Gibco BRL, Gaithersburg, MD.). To rule out false negative results, an internal control consisting of the housekeeping gene Glyceraldehyde 3-Phosphate Dehydrogenase (G3PDH), was ampli®ed using the same reaction conditions. This yielded a single DNA fragment of 452 bp. PCR speci®c primers for this reaction were: G3PDH3': 5'-ACCACGTCCATGCCAT-CAC-3'; G3PDH5': 5'-TCCACCACCCTGTT-GCTGTA-3'. The founder mice were mated with C57BL/6 mice to generate F1 mice.
Western-blot analysis of HK1.bcl-2 transgene expression Newborn pups were sacri®ced by rapid hypothermia and fresh tissue, including skin, was harvested. A small fragment of the skin, or other tissue, was placed in solubilization buer (0.0625 M Tris base, 5% (w/v) SDS, 10% (v/v) glycerol, 20% (v/v) 2-beta-mercaptoethanol, 0.05% (w/v) bromophenol blue) and homogenized by physical methods. The resulting suspension was boiled for 10 min and the remaining tissue fragments precipitated by centrifugation (14000 g, 5 min, 48C). The ®nal protein suspension was collected and stored at 7808C.
Protein samples were electrophoresed through a 10% acrylamide/bis-acrylamide minigel at 100 volts in a Miniprotean II System (Bio-Rad Laboratories, Hercules, CA) until the dye front reached the bottom of the gel, and then electrotransfered to a nitrocellulose membrane (NitroPlus, MSI, Westboro, MA) by using sequential increase of the dierential electric charge (15 min at 30 volts, 20 min at 70 volts, and 25 min at 100 volts). Correct protein electrophoretic separation and adequate transfer into the nitrocellulose membrane was con®rmed by staining the membrane with Ponceau S (0.1% w/v in 5% acetic acid) (Sigma, St Louis, MO), and the gel with Coomasie blue (Bio-Rad Laboratories, Hercules, CA).
To prevent nonspeci®c binding of antibodies, the membranes were then soaked in Tris Buered Saline solution (TBS) (0.02 mM Tris base, 0.137 M NaCl, pH 7.6) with 0.05% (v/v) Tween-20 (TBS-T) containing 5% Non-Fat Dehydrated Milk (NFDM), for 2 h, at room temperature. The membranes were exposed to a 1:2000 dilution in TBS-T/ 3% NFDM of the primary monoclonal antibody 6C8 (hamster anti-human Bcl-2 protein), for 1.5 h, at room temperature, with continuous shaking. Secondary rabbit anti-hamster IgG monoclonal antibody (PIERCE, Rockford, IL), diluted 1:2000 in TBS-T/3% NFDM, and a third horseradish peroxidase-labeled mouse anti-rabbit monoclonal antibody (Amersham Life Science, Arlington Heights, IL), diluted 1:3,000 in TBS-T/3% NFDM, were sequentially incubated for 1 hour each at room temperature. Chemoluminiscence ECL detection reagent (ECL system, Amersham Life science, Arlington Heights, IL) was applied to the membranes. Blots were exposed to Amersham hyper®lm. A t(14;18) translocation positive lymphoma cell line, expressing high levels of human bcl-2 protein, served as a positive control, and the Daudi lymphoma cell line, as a negative control. Equal loading of the samples was con®rmed by using an anti-actin mouse IgM monoclonal antibody (Amersham Life Science, Arlington Heights, IL) diluted 1:2000.
Immunohistochemical staining of transgenic human Bcl-2 Tissue samples were rapidly frozen in OCT embedding compound (Miles Inc., Elkhart, IN) and stored at 7808C. Frozen sections (5 ± 6 mm) were stained by the alkalinephosphatase-anti-alkaline-phosphatase (APAAP) technique. In brief, the sections were incubated with primary hamster anti-human bcl-2 monoclonal antibody 6C8 for 1 h at room temperature in a moist chamber, washed in Phosphate Buered Saline (PBS), and incubated with a secondary biotinylated goat anti-hamster monoclonal antibody (Vector Laboratories, Burlingame, CA) for 45 min. ABC Elite Kit (Vector Laboratories, Burlingame, CA) and ABC Chromagen (Biomeda, Foster City, CA) were used to develop the reaction. Counterstaining of the sections was done with Mayer's hematoxylin for one minute and rinsed in water.
Analysis of the proliferative index of the epidermis
The proliferative activity in epidermal keratinocytes was assessed by bromodeoxyuridine (BrdUrd) labeling as previously described (Sellheyer et al., 1993) . Brie¯y, newborn mice were injected intraperitoneally with a 10 mg/mL solution of 5-Bromo-2 ' -deoxyuridine 5'-Triphosphate (sodium salt) (BrdUrd; Sigma, St Louis, MO) in sterile saline solution (0.9% NaCl), 0.25 mg/g of body weight. One hour later the animals were sacri®ced, the skin was removed and ®xed in ethanol and paran embedded. Sections mounted on silane-coated slides were soaked overnight with an undiluted FITC-conjugated mouse monoclonal antibody anti-BrdUrd (Becton Dickinson Immunocytometric System, San Jose, CA) along with a guinea pig monoclonal antibody anti-mouse keratin 14 (provided by Dr Roop, Baylor College of Medicine). A biotinylated goat monoclonal antibody anti guinea pig IgG (Vector Laboratories, Inc., Burlingame, CA) (1:100 dilution in 12% bovine serum albumin, BSA), and streptavidin-Texas red¯uorochrome (Bethesda Research, Bethesda, MD) (®nal dilution 1:500 in 12% BSA), were sequentially applied to the slides for one hour each. Slides were then rinsed in PBS, covered with Fluormount G (Fisher Scienti®c, Pittsburgh, PA), and coverslipped. The slides were analyzed using a¯uorescence microscope (Nikon). BrdUrd-labeled nuclei were then quanti®ed morphometrically (number of stained nuclei per linear mm of epithelial basement membrane). The data were expressed as the percentage of BrdUrd positive nuclei and is referred to as the proliferative index.
Analysis of skin dierentiation
Skin samples from the back of newborn mice were rapidly frozen in OCT embedding compound (Miles Inc., Elkhart, IN) and stored at 7808C. Frozen sections (5 ± 6 mm thick) were evaluated immunohistochemically for expression of mouse keratins K1, K6, K10, K13, K14, ®laggrin, and loricrin using monoclonal antibodies developed by Roop and co-workers (Nischt et al., 1988; Roop et al., 1987; Rosenthal et al., 1991) . Sections were incubated overnight at room temperature in a moist chamber with rabbit monoclonal antibodies anti-murine K1, anti-murine K6, anti-murine K10, anti-®laggrin, and anti-loricrin. A guinea-pig anti-K14 antibody was simultaneously applied to all the sections to provide a counterstaining background. Stained sections were visualized by biotin-labeledguinea pig immunoglobulin and streptavidin-Texas red (Vector Laboratories, Inc., Burlingame, CA), and by FITC-labeled swine anti-rabbit immunoglobulin (DAKO, Carpinteria, CA). Stained sections were analysed bȳ uorescence microscopy and photographed using a Nikon Optiphot microscope assembled to a UFX-II High Performance Camera System, and mounted with a DM510 ®lter block for analysis of FITC immunostaining (excitation wavelength 488 nm, emission wavelength, 520 nm), and with a G-1B ®lter for Texas red immunostaining (excitation wavelength 596 nm, emission wavelength, 615 nm).
Determination of spontaneous apoptotic index of the epidermis
Thin sections of formalin ®xed and paran embedded skin were stained using the Terminal Deoxynucleotidetransferase Uridine End Labeling method (TUNEL) as described (Gavrieli et al., 1992) . Positive controls consisted of sections pretreated with DNase and the Tdt reaction step was omitted in the negative controls. Apoptotic indices were generated by counting 500 cells in each of ®ve dierent high-powered light microscopic ®elds. The apoptotic index was expressed as a percentage of cells labelled by the Tdt reaction over the total number of nucleated cells of the interfollicular segments of the epidermis.
Induction of sunburn cells
Newborn animals were exposed to a U.V. light emitting high-pressure mercury lamp to receive a dose of 2 J/cm 2 of U.V.-B light. This dose is able to induce in¯ammation and cell death in the epidermis of the exposed animals (Danno and Horio, 1987) . Twenty-four hours latter the animals were sacri®ced and skin samples from the exposed regions taken for histological processing and staining for light microscopy. The Sunburn Cell Index (SBI) was determine as percentage of sunburn cells over a minimum of 500 cells scored for each of ®ve HK1.bcl-2 and control animals.
Chemical carcinogenesis studies
Chemical carcinogenesis studies using newborn mice involved initiation by applying DMBA (20 mg in 200 ml of acetone) to the skin. At day 7, animals received 2.5 mg of TPA in 200 ml of acetone. Thereafter, TPA application was repeated twice/week until the animals reached one month of age. The TPA dose was then increased to 5 mg and continued with the same periodicity for 4 more months (total 30 weeks of TPA promotion). Skin tumors were scored and measured weekly.
